Howard Stern TRT: What Clinicians Should Tell Patients Who Ask

Why Patients Are Bringing Up Howard Stern in the Exam Room

Howard Stern has spoken on his SiriusXM program about using testosterone replacement therapy, describing symptoms that included fatigue and reduced libido before he began treatment. His candor is unusual for a major public figure, and it has measurably changed the questions some men bring to their physicians.

The "Celebrity Effect" on Patient Demand

When a high-profile personality discloses a diagnosis or treatment, patient search volume and clinical inquiries typically spike. A 2014 analysis published in the Journal of the American Medical Association documented this pattern with thyroid cancer after Angelina Jolie's BRCA disclosure, and the dynamic appears across specialties [1]. Testosterone prescriptions in the United States tripled between 2001 and 2011 before declining slightly after 2014 FDA safety communications, according to data reviewed by the FDA [2]. Celebrity disclosures are one driver, though direct-to-consumer advertising and online telehealth platforms contribute as well.

What Stern Actually Said (and What He Did Not)

Stern has described fatigue, mood changes, and low libido as his motivations for seeking TRT. He has not disclosed specific lab values, the preparation he uses, or his prescribing clinician's name. Clinicians should treat his statements as anecdote and frame them accordingly for patients. Inference beyond his own words is speculation, and this article labels any inference clearly.

The clinical takeaway: a patient who arrives citing Stern's experience is telling you something about his symptom burden and his openness to hormonal evaluation. That is a useful starting point, not a prescription trigger.

Diagnosing Hypogonadism: The Threshold That Actually Matters

Symptomatic hypogonadism requires both a biochemical and a clinical component before treatment is appropriate. Neither alone is sufficient for a diagnosis that justifies lifelong therapy.

Biochemical Criteria

The Endocrine Society's 2018 clinical practice guideline defines male hypogonadism as a total morning testosterone below 300 ng/dL confirmed on two separate fasting samples drawn before 10 a.m. [3]. The American Urological Association aligns with this threshold in its 2018 guideline on evaluation and management of testosterone deficiency [4].

Free testosterone calculation or direct assay adds clinical weight when total testosterone falls between 300 and 400 ng/dL, particularly in men with obesity or conditions that alter sex hormone-binding globulin. A reliable free testosterone calculation uses the Vermeulen equation; direct analog assays are less accurate and not recommended by most endocrine societies [3].

Symptom Criteria

The Endocrine Society requires at least one symptom from the classic hypogonadism cluster: decreased libido, erectile dysfunction, reduced spontaneous erections, breast discomfort, hot flashes, decreased energy, depressed mood, difficulty concentrating, sleep disturbance, or decreased shaving frequency [3]. Loss of body or facial hair and decreased testicular volume add clinical specificity.

Symptoms alone, without biochemical confirmation, should not prompt a TRT prescription. A 2016 randomized trial in the New England Journal of Medicine, the Testosterone Trials consortium (TTrials, N=790 men aged 65 and older with testosterone below 275 ng/dL), found that testosterone improved sexual function and physical performance scores vs. Placebo, but only in men who met both biochemical and symptomatic criteria [5].

Ruling Out Secondary Causes

Before prescribing, check LH and FSH to differentiate primary from secondary hypogonadism. A low testosterone with low or normal LH points toward a pituitary or hypothalamic cause. Prolactin, iron studies (to screen for hemochromatosis), and a pituitary MRI may follow depending on LH/FSH results. The Endocrine Society explicitly recommends this stepwise evaluation [3].

Evidence-Based Treatment Options

Once a diagnosis is confirmed, clinicians have several FDA-approved preparations. Choice depends on patient preference, fertility goals, cost, and comorbidities.

Injectable Testosterone

Testosterone cypionate and testosterone enanthate are the most widely used formulations in the United States. The Endocrine Society's 2018 guideline recommends 75 to 100 mg intramuscularly weekly, or 150 to 200 mg every two weeks [3]. Weekly dosing produces a more stable serum level and avoids the supraphysiologic peak and trough pattern associated with biweekly injection.

Testosterone undecanoate (Aveed) is a long-acting injectable dosed at 750 mg at weeks 0, 4, and then every 10 weeks. The FDA approved Aveed in 2014 with a REMS program requiring in-office administration due to risk of pulmonary oil microembolism [6].

Transdermal Preparations

Topical gels (AndroGel 1%, AndroGel 1.62%, Testim, Vogelxo) and solutions (Axiron) deliver testosterone transdermally. Absorption variability and transfer risk to partners and children are the primary limitations. Nasal gel (Natesto, 4.5 mg per nostril three times daily) avoids skin-transfer risk and may preserve spermatogenesis better than other routes, though data on that point remain limited [7].

Subcutaneous Pellets

Testopel pellets (75 mg each, typically 6 to 12 pellets per insertion) are placed subcutaneously in the upper buttock under local anesthesia every 3 to 6 months. Pellets are not adjustable once inserted, which creates a management problem if levels run high. Evidence for pellets is largely observational; no large randomized trials have directly compared pellets to injections on patient-centered outcomes.

HealthRX Clinical Decision Framework: Matching Formulation to Patient Profile

| Patient Profile | Preferred Formulation | Rationale | |---|---|---| | Cost-sensitive, comfortable with self-injection | Testosterone cypionate weekly SQ | Lowest cost, consistent levels | | Needle-averse, no female household members | Transdermal gel | Convenient; monitor for skin transfer | | Fertility preservation desired | hCG monotherapy or hCG + gel | Maintains intratesticular testosterone | | Partner-transfer concern | Nasal gel (Natesto) or injection | Eliminates topical transfer risk | | Non-adherent to weekly regimen | Testopel pellets or undecanoate | Less frequent dosing |

The TRAVERSE Trial: What It Changes for Cardiovascular Counseling

The cardiovascular safety of TRT was disputed for over a decade after two observational studies in 2013 and 2014 raised signals for increased myocardial infarction and stroke risk. The TRAVERSE trial resolved much of that uncertainty.

TRAVERSE Design and Results

TRAVERSE (Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE) enrolled 5,204 men aged 45 to 80 years with hypogonadism and pre-existing or high risk for cardiovascular disease. Participants received testosterone 1.62% gel or placebo for a median of 33 months. The primary endpoint was a composite of cardiovascular death, nonfatal MI, and nonfatal stroke [8].

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, showed a primary MACE rate of 7.0% in the testosterone group vs. 7.3% in the placebo group (hazard ratio 0.96; 95% CI 0.78 to 1.17; P<0.001 for non-inferiority) [8]. Testosterone was non-inferior to placebo for major adverse cardiovascular events.

Secondary Signals That Require Counseling

TRAVERSE did identify higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone group [8]. These are not reasons to categorically avoid TRT in cardiovascular patients, but they require individualized risk discussion. Clinicians should document that conversation.

The FDA updated its testosterone labeling in 2015 to require a warning about venous thromboembolism risk [2]. TRAVERSE corroborates that signal.

Hematologic Monitoring: The Hematocrit Rule

Testosterone stimulates erythropoiesis through EPO-dependent and EPO-independent pathways. Polycythemia is the most common dose-dependent adverse effect of TRT.

Monitoring Protocol

Check hematocrit at baseline, 3 months after starting or adjusting therapy, and annually once stable. The Endocrine Society and AUA both recommend withholding or reducing the testosterone dose if hematocrit exceeds 54% [3][4]. This threshold corresponds to the point at which blood viscosity increases measurably and VTE risk rises.

Men over 65, those with obstructive sleep apnea, smokers, and men living at high altitude are at greatest baseline risk for erythrocytosis on TRT. Screen for sleep apnea before starting therapy; untreated OSA can independently raise hematocrit and compounds the testosterone effect [3].

Managing Elevated Hematocrit

Options include dose reduction, switching to a preparation with lower peak levels (e.g., weekly injection instead of biweekly, or transdermal instead of injection), therapeutic phlebotomy, or treatment discontinuation. Therapeutic phlebotomy should not become routine practice to maintain a patient on a dose that consistently drives hematocrit above threshold; dose adjustment is the preferred first step.

Prostate Safety: What the Current Evidence Says

The historical concern that testosterone "feeds" prostate cancer originated with Charles Huggins's 1941 observation that castration caused prostate cancer regression, work that earned a Nobel Prize. The inverse assumption, that testosterone accelerates prostate cancer growth, was extrapolated without strong prospective evidence.

The Saturation Model

The saturation model, proposed by Morgentaler and Traish in 2009, holds that androgen receptors on prostate tissue reach saturation at relatively low testosterone concentrations (roughly 200 ng/dL), above which additional testosterone does not increase prostate cell proliferation [9]. This model has reshaped how many urologists approach TRT in men with treated, low-risk prostate cancer, though it remains an area of active research.

Current Endocrine Society guidelines still list active or suspected prostate cancer as an absolute contraindication [3]. The AUA guideline notes that TRT in men with a history of treated prostate cancer should be individualized and managed in consultation with urology [4].

PSA Monitoring

Check PSA at baseline and at 3 to 6 months after starting TRT. A rise in PSA of more than 1.4 ng/mL above baseline within the first year, or any PSA above 4.0 ng/mL, warrants urology referral before continuing therapy [3]. Digital rectal exam at baseline is recommended for men over 40, per the AUA guideline [4].

Fertility Preservation: The Conversation That Often Gets Skipped

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis through negative feedback, reducing LH and FSH. This suppresses intratesticular testosterone to levels too low for spermatogenesis, even when serum testosterone is supranormal.

Data on Testosterone-Induced Azoospermia

A 1990 WHO multicenter trial demonstrated that weekly testosterone enanthate 200 mg IM produced azoospermia in 65% of men and suppressed sperm counts below 3 million/mL in 98% of participants within 6 months [10]. This is the basis for ongoing research into testosterone as a male contraceptive, and it is directly relevant to any patient of reproductive age considering TRT.

Preserving Fertility While Treating Symptoms

Three options exist for men who want to maintain fertility potential while treating symptomatic hypogonadism:

1. Sperm cryopreservation before starting TRT. This is the most reliable option.
2. hCG monotherapy (1,500 to 3,000 IU subcutaneously two to three times per week) stimulates Leydig cells directly and maintains intratesticular testosterone and spermatogenesis in most men with secondary hypogonadism [3].
3. hCG co-administration with testosterone (250 to 500 IU hCG every other day) may partially preserve spermatogenesis during TRT, though evidence is largely observational and outcomes vary.

Clinicians who see patients of reproductive age should document a fertility discussion before prescribing. The American Society for Reproductive Medicine supports sperm banking as a reasonable precaution before gonadotoxic therapy [11].

How to Counsel the Patient Who Cites Howard Stern

When a patient says "Howard Stern takes TRT and he says he feels great," the clinical response should be empathetic, organized, and grounded in the patient's own data.

A Structured Response Framework

Start by validating the symptom report. Fatigue, low libido, and mood changes are real complaints with real differential diagnoses. TRT may be appropriate, but it is one item on a longer list that includes sleep disorders, depression, hypothyroidism, anemia, and medication side effects.

Then explain the diagnostic process. Tell the patient that a blood draw before 10 a.m., on two separate mornings, is the starting point. Frame it as: "We check your levels first, and if the numbers match your symptoms, we have good treatment options with strong evidence behind them."

What Not to Promise

Avoid implying that TRT will produce the same result for every patient. The TTrials showed significant heterogeneity in response; sexual function improved significantly in the testosterone group (mean IIEF score difference vs. Placebo: 2.64 points), but mood and depressive symptom scores showed more modest and variable effects [5]. A celebrity's report of feeling "great" reflects his individual physiology, his baseline testosterone level (unknown to us), and the placebo response component that any open-label self-report carries.

The Endocrine Society's 2018 guideline states: "We recommend against a broad population-based screening program for testosterone deficiency, as this practice has not been shown to improve outcomes" [3]. Screening based on celebrity identification with a public figure's symptoms is a version of that broad screening approach.

Documenting the Conversation

Document that the patient inquired about TRT, that you explained the diagnostic criteria, and that any prescription followed confirmed biochemical hypogonadism plus symptom criteria. This protects the patient from unnecessary lifelong therapy and protects the clinician from prescribing outside guideline thresholds.

Monitoring Schedule at a Glance

Once TRT is initiated, consistent monitoring prevents the most common adverse effects and confirms therapeutic response.

| Timepoint | Labs and Assessments | |---|---| | Baseline | Total testosterone (x2 fasting AM), free testosterone, LH, FSH, prolactin, CBC, CMP, PSA, lipid panel, DRE (age >40) | | 3 months | Total testosterone (mid-interval for injections), hematocrit, PSA, blood pressure, symptom review | | 6 months | Repeat if dose adjusted at 3 months; otherwise continue to annual | | Annually | Full panel: testosterone, hematocrit, PSA, lipids, CMP, symptom reassessment | | As needed | Sperm analysis if fertility concern arises; urology referral if PSA rise >1.4 ng/mL above baseline |

Target testosterone range during treatment is 400 to 700 ng/dL for most preparations, measured at the appropriate interval (trough for biweekly injections, mid-interval for weekly injections, 2 to 8 hours post-application for gels) per Endocrine Society guidance [3].